Stock Picks
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Buyer straight eating up all the shares. Big boys moving in. Again anyone selling now is a absolute idiot. I would be very surprised if we don’t hit .05-.10 next week.
As soon as selling dries up, we fly!!!
Yep. Huge buyer soaking up shares. It’s ready to pop to 5 cents easily next week
Far from it. It’s going to be a glorious New Year
You aren’t reading L2 right. They are holding it down and soaking them up. Watch the tape this week. It’s a thing of beauty.
Big buyer soaking up all the selling. Looks like they are taking it way up once you fools stop selling. Any news and we move big. Got my sell orders in ranging from at .20-.45
Buyer is soaking up shares. Love it. Selling will dry up for the next move up
Great $RAFA news! They are building an empire. Rafarma Merger Company Bebig Approved For Production And Sale Of Yttrium-90 For Treatment Of Inoperable Liver Cancer.
https://t.co/CVDLbE8Xs3?amp=1
Thanks for the update!
What’s their sound funding plan? I don’t follow it close enough.
Yes sir...RAFA has a ton in cash, so buying back shares makes a ton of sense. They just retired 5 million shares last week too!
Great News for $RAFA Thailand Division! The Food and Drug Administration (FDA) has finalized the regulation draft that will remove cannabis and hemp from Thailand’s list of narcotics!
“The ministry hopes that the removal of cannabis and hemp from narcotics list will help promote their cultivation as cash crops among local farmers as well as advance their applications in medical and healthcare industries,”
https://www.asiaone.com/asia/thai-ministry-allows-use-some-parts-hemp-cannabis-plants-recreational-use-still-banned
Glad to have you Dave. Pieces are coming together here.
-Largest shopping cart distributor in the world is a main investor. I’d assume they will be distributing the smart cart to their clients.
AAZZF News:
The Company raised gross proceeds of CAD$8,344,043 which will be used for the role out and marketing of our advanced Cust2mate products as well as corporate advancements. https://finance.yahoo.com/news/a2z-smart-technologies-provides-additional-140000110.html
One of the major investors in their smart cart is https://en.m.wikipedia.org/wiki/Wanzl_(company) Who are the largest manufactures of shopping carts in the world! 2 million carts per year!!!
Things are heating up.
That makes over 2000 employees now if you add all the divisions up!
Release the audits so the bigger funds can buy baby!!!
$RAFA Rafarma Pharmaceuticals welcomes SLAVICH
per our previously announced merger
http://slavich.ru
Produce photographic paper & plates, materials for Micro Electronics & various packaging products
Founded in 1931
900+ Employees
Includes 7 Factories
Has 14 Subsidiaries
$RAFA Rafarma Pharmaceuticals welcomes SLAVICH
— Rafarma Pharmaceuticals Inc (@RafarmaPharma) November 18, 2020
per our previously announced mergerhttps://t.co/sgULx0vMRn
Produce photographic paper & plates, materials for Micro Electronics & various packaging products
Founded in 1931
900+ Employees
Includes 7 Factories
Has 14 Subsidiaries pic.twitter.com/0k2rKKSswD
$RAFA - Rafarma Pharmaceuticals welcomes BEBIG per our previously announced merger
http://en.bebig.ru
BEBIG was founded in 2004 in order to introduce high-tech and innovative cancer treatment methods
29 Medical Centers
8,000+ Patients Treated
1,000+ Operations Performed
$RAFA - Rafarma Pharmaceuticals welcomes BEBIG per our previously announced mergerhttps://t.co/EyGZKElFgz
— Rafarma Pharmaceuticals Inc (@RafarmaPharma) November 18, 2020
BEBIG was founded in 2004 in order to introduce high-tech and innovative cancer treatment methods
29 Medical Centers
8,000+ Patients Treated
1,000+ Operations Performed pic.twitter.com/2SJSEBDlT5
Yes! Marty is here!
Looks like we are the only 2 people here. It’s a steal at .50. I’m accumulating.
Updated
Merger Has Already Closed.
-The Company has announced elite Chicago auditing firm and we are just waiting on the audited numbers for take off and then I assume an uplist to a much higher exchange.
https://seekingalpha.com/news/3623390-rafarma-closes-merger-biogency-laboratories
GREAT UPDATE TODAY! The merger increased Rafarma Pharmaceuticals 2019 revenues from $11.4 million to $84 million!!!
Reverse Merger of Biocogency into Rafarma Pharmaceuticals Creates Substantial Unrealized Shareholder Value
November 17, 2020 -- InvestorsHub NewsWire -- via BioResearch Alert --
Biocogency with $73 million 2019 sales recently acquired majority control and merged all operations into Rafarma Pharmaceuticals
There was no dilution to Rafarma shareholders and all operations and assets of both companies will be combined and reported under the ticker RAFA
The merger increased Rafarma Pharmaceuticals 2019 revenues from $11.4 million to $84 million
Elite accounting firm, L. J. Soldinger is retained to perform audited financials
Wealthy international industrialist, Ilya Shpurov is now Chairman of the Board of Rafarma Pharmaceuticals
With 2019 combined sales of $84 million, current market cap of $131 million, extraordinary strong growth, and share price of $1.69, market comps point to share price valuation several multiples higher than current price
Many OTC stocks are easily overlooked because they don't get the coverage of peers traded on national exchanges and consequently very few investors have the opportunity to know about them. A perfect example is the recent closing of a reverse merger increasing sales by over 700% and adding sizable international operations of private Biocogency into Rafarma Pharmaceuticals (OTC: RAFA) where the RAFA share price has not yet reflected the new added value.
On October 19, 2020, the merger of Biocogency into Rafarma was announced and went unnoticed. Although important metrics to determine share valuations have soared as a result of the merger, the share price has not yet caught up reflecting the new increased valuations simply because nobody knows about it yet. As word is likely to spread soon, the share price is expected to begin climbing to more fair and reasonable market valuations that could exceed expectations.
About Rafarma Pharmaceuticals
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells cannabis health-related products and specialty pharmaceuticals. The company formerly known as Johnston Acquisition Corp. changed its name to Rafarma Pharmaceuticals, Inc. and is based in Sandy, Utah with a manufacturing and distribution facility in Russia.
About Biocogency
Biocogency owns PJSC "Krasfarma", the largest Russian chemical and pharmaceutical production company with more than 50 years of experience in the production of drugs that meet all national and international quality standards.
The Company helps meet the growing needs of health care for high-quality, effective and safe generic pharmaceuticals as well as development and production of innovative pharmaceutical products. Production systems with a strong emphasis on safety are carried out through a coordinated interaction of their quality control department, commercial department, logistics service, and scientific information department and pharmacovigilance services.
A rich history is not the most important thing in the modern pharmaceutical industry. To keep the quality of products on a permanently high level, a program of production modernization is being realized: investments in the company include new industrial lines, engineering systems and control systems, as well as new pharmaceutical products.
Safe and effective generic medicines of PJSC "Kraspharma", which are not inferior in clinical efficacy to the original, but sold at affordable prices, have won the trust of both doctors and patients.
Today PJSC "Kraspharma" is the Eastern Europe and Russia undisputed leader in the production of:
Antibiotics;
tuberculosis drugs in injectable forms;
Blood substitutes;
infusion solutions;
Preparations of other pharmacological groups.
Most of the drugs produced are included in Vital and Essential Drugs List (VED) approved by the Government of the Russian Federation.
The products of PJSC "Kraspharma" are sold in Russia, Eastern Europe, Central Asia and in the countries of the Asia-Pacific region.
What Biocogency Adds to Rafarma
This transformative merger starts by restating Rafarma 2019 sales from $11.4 million to $84 million and delivers impressive growth rates of close to 50%.
The Biocogency group includes Russia-based drug companies Bebig and PJSC Kraspharma and industrial firm Slavich. Bebig is focused on developing therapies and diagnostics for cancer care in the Russian markets, including supplying microsources for the treatment of prostate cancer using low-dose brachytherapy. Kraspharma, Russia's largest chemical and pharmaceutical production company (and crown jewel of the merger), and Slavich, a manufacturer of a variety of products including packaging goods, materials for microelectronics and photo materials, are both steeped in corporate history going back half a century or more in Russia.
Biocogency also brings leadership committed to growing value as measured by the fact the deal was structured to be non-dilutive to existing RAFA shareholders. To that point, Ilia Shpurov has assumed the position of Chairman of the Board, bringing decades of entrepreneurial – and biotech – success to RAFA.
What's in it for RAFA? An Immediate Spike in Revenue and Profits
The merger with Biocogency is a game changer for RAFA operations and the top and bottom lines. Consider that in 2019, RAFA generated revenue of approximately $11.4 million and gross profit of $3.4 million. In the latest quarter, ended July 31, 2020, Rafarma reported revenue of $5.3 million and gross profit of $3.1 million, according to filings with OTC Markets Group.
Those results are going to get an immediate shot of adrenaline.
During fiscal 2019, the Biocogency group reported unaudited consolidated earnings of $73 million and gross profits of $17 million. As a course of becoming fully reporting and planning to uplist, the financial results are being audited and adjusted to meet GAAP standards.
Using the results from 2019, it is easy to extrapolate pro forma revenue of $84.4 million and gross profit of $20.3 million for the combined company. It is those type of financials that will underpin a move to the Nasdaq or NYSE.
More on how the price to sales ratio stacks up to industry comps are discussed here. Several Pharmaceutical market comps point to Rafarma share prices that are many multiples higher than the current price of $1.69.
When it comes to value, it certainly bears mentioning the investments that Biocogency has put into its pipeline and platforms since 2012, which management pegs at more than $120.0 million. Much of this investment has been directed by Shpurov since he bought the Kraspharma during the outbreak of the global financial collapse in 2008 for the purpose of restoring and expanding production volumes post-recession while establishing a high-tech GMP pharmaceutical manufacturer in Krasnoyarsk.
That was accomplished. Today, Kraspharma is a leading producer of wide swath of generic drugs and pharma products spanning antibiotics, blood substitutes, infusion solutions, tuberculosis and preparations for other pharmacological groups. Sales channels extend throughout Russia, Eastern Europe and the Asia-Pacific region.
Widening the Footprint
The plan is for vertical growth by expanding the existing channels while leveraging RAFA relationships for horizontal growth through entering the lucrative North American markets.
In fairness, Russia alone can be a company maker. A huge net importer of medicine, the Russian government is pushing for national security in the supply chain as outlined in the Pharma 2030 Strategy. With that in mind, Statista forecasts the Russian pharmaceutical industry will grow 147% between 2017 and 2030.
During Q1, the Russian pharma market surged 125% year-over-year to about 320 billion Russian rubles (US$4.2 billion). Generic drugs typically dominate the prescription market, accounting for 64.5% of the category in 2017, meaning Kraspharma is in a strong position.
Given the sheer volume of people, Asia is another tremendous market. The Rx market in China alone is forecast to reach $160 billion by 2022, highlighting the market opportunity. With respect to the Asian drug development market, ResearchAndMarkets estimates 6.54% compound annual growth to reach $62.46 billion by 2026.
Still, the U.S. is the Holy Grail as the biggest pharmaceutical market in the world, weighing in at a whopping $484.4 billion in 2018.
Conclusion
With the reverse merger now closed, the newly created Rafarma Pharmaceuticals that now boasts fast-growing operations well in excess of $100 million for 2019 is decidedly undervalued when compared to industry valuations for similar companies. Management plans for uplisting and higher investor awareness programs are soon in the future which will help bring the Rafarma opportunity to the forefront resulting in substantially higher prices and trading volume.
The current price has not yet appreciated to reflect the newly increased sales and valuations and therefore presents an opportunity to astute investors who act now before the story becomes more commonly known.
https://ih.advfn.com/stock-market/USOTC/rafarma-pharmaceuticals-pk-RAFA/stock-news/83705688/reverse-merger-of-biocogency-into-rafarma-pharmace
A2Z Smart Technologies Announces Final Closing of its previously announced Private Placement for aggregate gross proceeds of CAD$8,344,043 and Completion of the Acquisition of 77.51% of Cust2Mate Ltd.
TEL AVIV, ISRAEL / ACCESSWIRE / November 16, 2020 / A2Z Smart Technologies Corp. ("A2Z" or the "Company") (TSXV:AZ)(OTCQX:AAZZF), an innovative technology company specializing in state-of-the-art automation and electronics technology, is pleased to announce that it has closed its previously announced private placement (the "Offering") of subscription receipts. The Company has issued 13,350,460 subscription receipts which were, immediately prior to the closing of the acquisition (as defined below) automatically exercised into 13,350,460 units (the "Units") at a price of $0.625 per Unit for gross proceeds of CAD$8,344,043. Each Unit is comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (each, a "Warrant"). Each Warrant entitles the holder thereof to purchase one additional Common Share at a price of $0.90 at any time prior to November 10, 2025.
In connection with the Offering, the Company paid finders' fees of $417,202 in cash (of which $360,727 was paid to Orion Underwriting).
All securities issued in connection with the Offering are subject to a four month and one day hold period expiring on March 11, 2021.
The Company is also pleased to announce that it has completed the acquisition of 77.51% of Cust2mate Ltd., (the "Cust2Mate Shares") a technology company specializing in smart shopping carts technology. The Cust2Mate Shares were purchased from Mr. Bentsur Joseph, who is also the Company's Chief Executive Officer and a director. The Company paid total consideration for the Cust2Mate Shares of US$1,566,000 from the proceeds of the Offering. Mr. Bentsur Joseph, no longer owns any securities of Cus2mate.
The Company intends to use the remaining proceeds of the Offering for product marketing, manufacturing, integration of the Cust2mate business and general corporate purposes.
About Cust2mate Ltd. - Cust2Mate is a technological company focused on providing retail automation solutions, in particular for large grocery stores, supermarkets and retail stores. Cust2Mate's primary product is the Cust2Mate system which incorporates a "smart cart" enabling shoppers to checkout automatically without having to pass through the cashier, unload and reload their purchases by simply allowing the costumer to "pick&go".
About A2Z Smart Technologies, Inc.
A2Z Smart Technologies, Inc. is an innovative technology company based out of Israel, specializing in military technology and expanding into the civilian markets. A2Z has been operating for over 30 years and has a client base with 75 recurring clients, including the Israel Defense Forces, Security Forces, and Ministry of Defence among others. A2Z plans to leverage their cash flow-generating core-business to expand into the civilian robotics and automobile markets.
For additional information, please visit: https://a2zas.com
Twitter: @a2z_advanced
Instagram: a2z_smart_tech
On Behalf of the Company,
Bentsur Joseph, CEO
https://www.otcmarkets.com/stock/AAZZF/news/story?e&id=1743383
Moved on. I didn’t like the action after the news. I thought it would go up a lot more than it did
Big Rafa News!
-Rafarma will file a Form 10 to become a fully-reporting company, with plans thereafter to uplist the company to a major exchange.
-Cancellation of 5.4 million common shares
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201109:nGNXYPvFW
No, I don’t have timing. I’m hopeful that it will be complete by end of November.
This thing is so thin, it should literally fly a few dollars when buyers start coming in.
I always keep a bid in, in case someone wants to come down and sell to me.
Merger, then audited financials, then uplist.
LJ Soldinger Associates are very reputable...they were recognized as 4th in the World for net new PCAOB public company audits in Q4 2019.
Some big names as past clients!
https://www.irglobal.com/article/l-j-soldinger-associates-llc-recognized-as-4th-in-the-world-for-net-new-pcaob-public-company-audits-in-q4-2019/
Huge News! Elite Chicago auditing firm LJ Soldinger Associates Retained!
Auditing Firm L J Soldinger Associates Retained for Rafarma Biocogency Merger
Nicosia, Cyprus, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals,
Inc. OTC:(RAFA) is pleased to announce that the elite Chicago auditing firm LJ
Soldinger Associates (https://www.soldinger.com/) has been retained to provide
auditing services for the resulting Rafarma group of companies from the
Biocogency/Rafarma merger.
Ilya Spurov, Chairman of Rafarma, commented: “The reputation of LJ Soldinger
Associates gives us confidence that our transition will be smooth,
professional and efficient.”
https://www.bloomberg.com/press-releases/2020-11-04/auditing-firm-l-j-soldinger-associates-retained-for-rafarma-biocogency-merger
It’s a winner. Anyone selling now is a idiot. The PR train is just starting.
I’m looking for .50 by end of November & $1 by end of the year! Company pipeline looks amazing.
This will go $1-$2. Lots of good news coming out. I know a lot of people accumulating right now.
Adding today. Make sure you have your full position. I think this stock is about to take off.
Why is he going to jail?
Huge $RAFA News! Big Time Revenue Coming in Now!
Nicosia, Cyprus, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that it has closed the merger with BIOCOGENCY LABORATORIES. The new consolidated financials will include Slavich (http://www.slavich.ru), Slavich Trading House and related companies based in Spain, Ireland and Cyprus, with Kras Pharma (http://kraspharma.ru) and Bebig (http://en.bebig.ru/) being added in due course.
The company’s Slovenian assets will be divested, per the merger agreement.
Vladimir Dolgolenko, CEO of Rafarma, commented: “the new chapter has officially begun. We are very excited.”
When asked about next steps, new Chairman Ilya Spurov stated: “We are already moving promptly in optimizing Rafarma’s assets to conform our U.S. strategy. My main goal is to provide all the old shareholders as well as the new ones the maximum possible market capitalization and stock liquidity through development and introduction of new products and obtaining new sales channels in the nearest possible future.”
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201019:nGNXbbCJMt
Sweet update on $RAFA! Revenues projected to increase to $84 million on the imminent merger close.
Imminent Windfall For Rafarma Pharmaceuticals Shareholders Confirmed By Recent Approval Of Majority Vote To New Incoming Chairman Ilya Shpurov
https://seekingalpha.com/instablog/21922151-bioresearch-alert/5506272-imminent-windfall-for-rafarma-pharmaceuticals-shareholders-confirmed-recent-approval-of
Let’s see those audits. Gonna be glorious when they drop them.
LOL. Audits on the way bud and once released the huge buying begins.
LOL. Get a new streamer. Big boys just stepped in and my guess is they are about to come with some thunder over the next few weeks.